Solute Carrier Family 28 Member 3 (SLC28A3) Genotyping
SLC28A3 (solute carrier family 28 member 3) is a sodium-coupled nucleoside transporter that is responsible for the influx of a variety of substances and xenobiotics into the cell. The transporter is encoded by the SLC28A3 gene located at 9q21.32-21.33. The transporter plays a vital role in the transport of drugs into cells that act on nucleosides including anti-neoplastic drugs like anthracycline drugs (Doxorubicin, Daunorubicin, Epirubicin, Idarubicin, and Valrubicin). These drugs act by poisoning topoisomerase II, intercalating into DNA, generating reactive oxygen species (ROS), and ultimately damaging the DNA. Cancer cells with anthracycline-mediated DNA damage undergo apoptosis.
While administering anthracyclines to patients, anthracycline-induced cytotoxicity is a major concern with a prevalence of up to 57%. Although cardiotoxicity may result from various factors including drug dosage and cardiac irradiation, studies have proved that certain genetic variants and single nucleotide polymorphisms (SNPs) in SLC28A3 are associated with higher susceptibility to anthracycline-induced cardiotoxicity. Various studies have found that variant rs7553758 has been associated with cardiotoxic syndromes following anthracycline administration. The toxicity is clinically similar to congestive heart failure and left ventricular dysfunction. Toxicity can be monitored by monitoring the patient’s left ventricular ejection fraction.
The mechanism underlying toxicity appears to be due to accumulation of anthracycline in cells. SNPs on the SLC28A3 gene may diminished transporter transcription such that anthracyclines are not transported into the nucleus and accumulate in the cell cytoplasm. Genetic testing for SNPs in the SLC28A3 gene has been suggested as an aid in identifying patients who have the A-allele variant rs7853758 who are at risk for anthracycline-induced cardiotoxicity. However, current evidence and consensus recommendations do not recommend genetic screening prior to initiating anthracycline therapy.
- Useful in predicting anthracycline-induced cardiotoxicity
- Aids in the selection of appropriate anti-cancer drugs
A positive result indicates the presence of variant rs7853758 in the SLC28A3 gene. The result is further interpreted as:
- Low risk: individuals with A/G allele. (Heterozygous)
- High risk: individuals with A/A allele. (Homozygous)
Negative (rs7853758 G/G indicated normal SLC28A3 transporter functioning)
Whole blood (EDTA), buccal swab, saliva.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: unstable
- Pediatr Blood Cancer. 2013 Aug;60(8):1375-81. [PMID: 23441093]
- J Clin Oncol. 2012 May 1;30(13):1422-8. [PMID: 21900104]
- Genet Test Mol Biomarkers. 2018 Nov;22(11):652-655. [PMID: 30351207]
- Circulation. 2022 Jan 25;145(4):279-294. [PMID: 34874743]
- Pharmacogenomics. 2016 Feb;17(3):231-40. [PMID: 26799497]